The earnings call reflects strong growth and strategic positioning of Tarsus, with significant achievements in sales, financing, and market expansion. While there are operational challenges and increased expenses, the overall outlook remains positive due to strong demand and strategic initiatives.

Company Guidance -

Q3 2025

In the Tarsus First Quarter 2025 Earnings Conference Call, key metrics highlighted include a significant sales growth for XDEMVY, with over $78 million in sales, marking a 217% increase year-over-year. Approximately 72,000 bottles were dispensed, driven by strong execution and market expansion efforts. The company also reported a gross margin of around 93% and a gross to net discount of approximately 47%. Tarsus ended the quarter with $407.9 million in cash and cash equivalents, bolstered by a recent $135 million equity raise. The call outlined plans for a Phase 2 trial for TP-04 in Ocular Rosacea, while emphasizing the impact of their direct-to-consumer campaign, which increased website visits by 140% from December 2024 to March 2025. Additionally, they have secured more than 90% coverage for commercial and Medicare lives, facilitating broader patient access.

Remarkable Sales Growth of XDEMVY

XDEMVY sales surpassed $78 million in the first quarter, marking a year-over-year increase of 217%, driven by approximately 72,000 bottles dispensed.

Significant Equity Financing

The company secured approximately $135 million through an oversubscribed and upsized equity financing, indicating strong shareholder confidence.

Global Expansion Opportunities

Tarsus is exploring global opportunities for XDEMVY, with potential European regulatory approval on track for 2027 and ongoing discussions for entry into the Japanese market.

Strong Commercial and Medicare Coverage

More than 90% of commercial and Medicare lives are covered, reducing hurdles for physician adoption and increasing patient access.

Positive Impact of DTC Campaign

Direct-to-consumer advertising increased average weekly website visits by 140% and drove thousands of patients to take the DB quiz weekly.

Tarsus Pharmaceuticals (TARS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TARS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.32 / -	-0.61	―	―	―
Aug 06, 2025	2025 (Q2)	-0.38 / -0.48	-0.88	45.45% (+0.40)
May 01, 2025	2025 (Q1)	-0.73 / -0.64	-1.01	36.63% (+0.37)
Feb 25, 2025	2024 (Q4)	-0.74 / -0.60	-1.31	54.20% (+0.71)
Nov 13, 2024	2024 (Q3)	-0.94 / -0.61	-1.28	52.34% (+0.67)	―
Aug 08, 2024	2024 (Q2)	-0.92 / -0.88	-1.17	24.79% (+0.29)	―
May 08, 2024	2024 (Q1)	-1.18 / -1.01	-0.88	-14.77% (-0.13)	―
Feb 27, 2024	2023 (Q4)	-1.37 / -1.31	-0.46	-184.78% (-0.85)	―
Nov 09, 2023	2023 (Q3)	-1.35 / -1.28	-0.84	-52.38% (-0.44)	―
Aug 10, 2023	2023 (Q2)	-1.08 / -1.17	-0.24	-387.50% (-0.93)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TARS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 01, 2025	$50.30	$47.36	-5.84%
Feb 25, 2025	$45.54	$41.29	-9.33%
Nov 13, 2024	$46.50	$46.65	+0.32%
Aug 08, 2024	$23.61	$26.85	+13.72%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Tarsus Pharmaceuticals, Inc. (TARS) report earnings?

Tarsus Pharmaceuticals, Inc. (TARS) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Tarsus Pharmaceuticals, Inc. (TARS) earnings time?

Tarsus Pharmaceuticals, Inc. (TARS) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TARS EPS forecast?

TARS EPS forecast for the fiscal quarter 2025 (Q3) is -0.32.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing